OptiNose Inc. (OPTN)
9.10
0.03 (0.33%)
At close: Apr 14, 2025, 1:00 PM
0.33% (1D)
| Bid | 9.09 |
| Market Cap | 92.16M |
| Revenue (ttm) | 78.23M |
| Net Income (ttm) | -21.54M |
| EPS (ttm) | -2.12 |
| PE Ratio (ttm) | -4.29 |
| Forward PE | -2.19 |
| Analyst | Hold |
| Ask | 9.14 |
| Volume | 70,335 |
| Avg. Volume (20D) | 98,957 |
| Open | 9.11 |
| Previous Close | 9.07 |
| Day's Range | 9.05 - 9.13 |
| 52-Week Range | 4.82 - 20.02 |
| Beta | -0.88 |
About OPTN
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb c...
Sector Healthcare
IPO Date Oct 13, 2017
Employees 127
Stock Exchange NASDAQ
Ticker Symbol OPTN
Website https://www.optinose.com
Analyst Forecast
According to 3 analyst ratings, the average rating for OPTN stock is "Hold." The 12-month stock price forecast is $9, which is a decrease of -1.10% from the latest price.
Stock ForecastsNext Earnings Release
OptiNose Inc. is scheduled to release its earnings on May 13, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 weeks ago
+52.5%
OptiNose shares are trading higher after Paratek P...
Unlock content with
Pro Subscription
5 months ago
-21.88%
OptiNose shares are trading lower after the company reported worse-than-expected Q3 revenue results and cut its FY24 net revenue guidance.
